Intraaortic Balloon Pump in Cardiogenic Shock II (IABP-SHOCK II)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00491036
Recruitment Status : Completed
First Posted : June 25, 2007
Last Update Posted : May 2, 2017
Information provided by (Responsible Party):
Holger Thiele, University of Leipzig

June 22, 2007
June 25, 2007
May 2, 2017
June 2009
June 2012   (Final data collection date for primary outcome measure)
30-day mortality [ Time Frame: 30 day ]
mortality [ Time Frame: 30 day ]
Complete list of historical versions of study NCT00491036 on Archive Site
  • Inflammatory markers (CRP and white blood cell count) [ Time Frame: 4 days ]
  • Hemodynamic Parameters (Blood pressure, Heart rate) [ Time Frame: 3 days ]
  • Time till hemodynamic stabilization [ Time Frame: 30 days ]
  • Catecholamine dose and duration of catecholamines [ Time Frame: 30 days ]
  • Mean and area under the curve of serum lactate [ Time Frame: 48 hours ]
  • Creatinine clearance until stabilization [ Time Frame: 4 days ]
  • requirement for hemofiltration or dialysis [ Time Frame: 4 days ]
  • length of ICU stay [ Time Frame: 30 days ]
  • length of mechanical ventilation [ Time Frame: 30 days ]
  • SAPS-II Score [ Time Frame: 4 days ]
  • requirement for active assist device implantation or heart transplantation at 30 days and approximately 60 months [ Time Frame: 60 months ]
  • long-term mortality at 6, 12 and approximately 60 months [ Time Frame: 60 months ]
  • quality of life at 30 days and approximately 60 months [ Time Frame: 60 months ]
Key secondary endpoint(s): hemodynamic parameters, catecholamine dose, APACHE-II-score, inflammatory markers, serum lactate Assessment of safety: major bleeding complications, peripheral ischemic vascu-lar complications [ Time Frame: 30 days ]
Not Provided
Not Provided
Intraaortic Balloon Pump in Cardiogenic Shock II
Randomized Clinical Study of Intraaortic Balloon Pump Use in Cardiogenic Shock Complicating Acute Myocardial Infarction

Patients in cardiogenic shock complicating acute myocardial infarction (AMI) are referred to a tertiary care center for percutaneous coronary intervention (PCI) of the infarct related artery in this multicenter, ran-domized clinical trial. After checking in- and exclusion criteria computerized randomization is performed to either PCI plus intraaortic balloon pump (IABP) insertion and medical treatment or PCI plus medical treatment only. Intensive care treatment is performed according to standard care including hemodynamic monitoring using a pulmonary artery catheter for optimal volume status adaptation and inotropic drug administration.

The IABP will be weaned after hemodynamic stabilization. Primary outcome measure will be 30-day mortality. The secondary outcome measures such as hemody-namic, laboratory and clinical parameters will serve as surrogate for prognosis of the patients.

Not Provided
Phase 4
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
  • Myocardial Infarction
  • Shock, Cardiogenic
Device: Intraaortic balloon pump
intraaortic balloon pump from Datascope/Maquet or Arrow/Teleflex will be used
  • Active Comparator: Intraaortic balloon pump
    Patients in cardiogenic shock get an intraaortic balloon pump in the cath lab
    Intervention: Device: Intraaortic balloon pump
  • No Intervention: No intraaortic balloon pump
    Patients in cardiogenic shock in this group get no intraaortic balloon pump

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
Not Provided
October 2016
June 2012   (Final data collection date for primary outcome measure)

Inclusion Criteria:

Cardiogenic shock complicating acute myocardial (STEMI or NSTEMI) with

  • intended revascularization (PCI or CABG)
  • Systolic blood pressure < 90 mmHg > 30 min or inotropes required to maintain pressure > 90 mmHg during systole
  • Signs of pulmonary congestion
  • Signs of impaired organ perfusion with at least one of the following:

    • Altered mental status
    • Cold, clammy skin
    • Urine output <30 ml/h
    • Serum lactate >2mmol/l
  • Informed consent

Exclusion criteria:

  • Resuscitation > 30 minutes
  • Cerebral deficit with fixed dilated pupils
  • No intrinsic heart action
  • Mechanical infarction complication
  • Onset of shock > 12 h
  • Severe peripheral artery disease
  • Aortic regurgitation > II.°
  • Age > 90 years
  • shock of other cause
  • Other severe concomitant disease
  • participation in another trial
Sexes Eligible for Study: All
18 Years to 90 Years   (Adult, Senior)
Contact information is only displayed when the study is recruiting subjects
Not Provided
Not Provided
Holger Thiele, University of Leipzig
University of Leipzig
Not Provided
Study Chair: Holger Thiele, MD Heartcenter Leipzig GmbH
University of Leipzig
May 2017

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP